– USA, MA – AltrixBio, a leading early-stage biotech startup, today announced the appointment of John Brooks to its Board as an Independent Director.
“We are thrilled to have John Brooks join our Corporate Board as an independent member. We are committed to helping people with Type 2 Diabetes, and obesity live longer, better, healthier lives. We are confident that John’s experience and expertise will help our team achieve this outcome more effectively,” said CEO, Nancy Briefs.
About John L Brooks III
John Brooks brings over three decades of experience working with early-stage life sciences companies developing innovative solutions to obesity, pre-diabetes, and diabetes. Brooks served as the President and CEO of the Joslin Diabetes Center, the world’s preeminent diabetes research, clinical care, and education organization. He also served on the community advisory board of the American Diabetes Association New England Chapter. In addition, Brooks co-founded numerous life sciences companies and is the managing director of Healthcare Capital LLC, an early-stage life science advisory and investment firm.
“The worsening obesity and T2D epidemics demand innovative solutions that promote patient health without compromising their quality of life,” said John Brooks. “AltrixBio is replicating the effect of gastric bypass surgery for T2D patients, and I’m looking forward to helping advance their efforts to provide a safe and effective alternative to invasive surgery.”
About AltrixBio
AltrixBio was founded in 2019 to commercialize the research from the labs of Dr. Karp and Dr. Tavakkoli at Brigham and Women’s Hospital and Harvard Medical School. The specialists were fascinated by the rapid resolution of Type 2 Diabetes seen in patients undergoing gastric bypass. They hypothesized that a drug was capable of adhering to the proximal bowel and could replicate the effect of surgery. Their work has led to the development of LuCI, which in pre-clinical models has been shown to modulate nutrient contact with the bowel mucosa and lower the glucose response, as confirmed in the group’s recent publication in Metabolism. LuCI temporarily binds to the proximal gut and acts locally without systemic absorption and likely limited side effects. LuCI has unique qualities that may allow it to act as a platform for the delivery of biologics to the GI tract as well.
For more information: https://www.altrixbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.